Clinical Applications

  • Keiko Esaki
  • Philip T. Chapman


A large number of mouse monoclonal antibodies have been applied to cancer, infectious diseases and thrombosis for therapeutic purposes. However, their therapeuticeutic effects in human patients are limited, due to their high immunogenicity in humanp atients. To eliminate this immunogenicity, the humanization of mouse antibodies has been established using genetic engineering technology.


Sensor Chip Dissociation Rate Constant Chimeric Antibody Association Rate Constant Hepes Buffer Saline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig M (1993) Reshaping a Human Antibody to Inhibit the Interleukin 6-dependent Tumor Cell Growth. Cancer Res. 53: 851–856PubMedGoogle Scholar
  2. 2.
    Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig M (1994) Humanization of a mouse anti-human Interleukin-6 receptor antibody comparing two methods for selecting human framework region. Mol. Immunol. 31: 371–381PubMedCrossRefGoogle Scholar
  3. 3.
    Suva L, Winslow G, Wettenhall R, Hammonds R, Moseley J, Diefenbach-Jagger H, Rodda C, Kemp B, Rodriguez H, Chen E, Hudson P, Martin T, Wood W (1987) A Parathyroid Hormone-Related Protein Implicated in Malignant Hypercalcemia: Cloning and Expression. Science 237: 893–896PubMedCrossRefGoogle Scholar
  4. 4.
    Sato K, Yamakawa Y, Shizume K, Satoh T, Nohtomi K, Demura H, Akatsu T, Nagata N, Kasahara T, Ohkawa H, Ohsumi K (1993) Passive Immunization with Anti-Parathyroid Hormone-Related Protein Monoclonal Antibody Markedly Prolongs Survival Time of Hypercalcemic Nude Mice Bearing Transplanted Human PTHrP-Producing Tumors. J. Bone Mineral Res. 8: 849–860CrossRefGoogle Scholar
  5. 5.
    Onuma E, Sato K, Kaiho S, Miura M, Takahashi S, Ogata E (1999) The role of PTHrP in malignancy-associated hypercalcemia and cachexia. Cancer-Induced Bone Diseases, Second International Conference, Abstract 23Google Scholar
  6. 1.
    Wolfgang L G, Csernokt E, Helmchen U (1995) Antineutrophil cytoplasmic autoantibodies, autoantigens and systemic vasculitis. Acta Pathol. Microbiol. Scandanavica 103: 81–97Google Scholar
  7. 2.
    Johne B, Gadnell M, Hansen K (1993) Epitope mapping and binding kinetics of monoclonal antibodies studied by real time biospecific interaction analysis using surface plasmon resonance. J. Immunol. Methods 160: 191–198PubMedCrossRefGoogle Scholar
  8. 3.
    Laricchia-Robbio L, Liedberg B, Platou-Vikinge T, Rovero P, Beffy P, Revoltella R P (1996) Mapping of monoclonal antibody and receptor binding domains on human granulocyte-macrophage colony stimulating factor (rhGM-CSF) using a surface plasmon resonance based biosensor. Hybridoma 15: 343–350PubMedCrossRefGoogle Scholar
  9. 4.
    Savage C O S, Winearls C G, Jones S, Marshall P D, C.M. Lockwood (1987) Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet 20/6: 1389–1393CrossRefGoogle Scholar
  10. 5.
    Zhao M H, Lockwood C M (1996) A comprehensive method to purify three major ANCA antigens:- proteinaise 3, myeloperoxidase and bactericidal permeability increasing protein from human neutrophil granule acid extract. J. Immunol. Methods 197: 121–130PubMedCrossRefGoogle Scholar
  11. 6.
    MacDonald R A, Hosking C S, Jones C L (1988) The measurement of relative antibody affinity by ELISA using thiocyanate elution. J. Immunol. Methods 106: 191–194PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2000

Authors and Affiliations

  • Keiko Esaki
    • 1
  • Philip T. Chapman
    • 2
  1. 1.Pharmaceutical Technology Lab.Chugai Pharmaceutical Co., Ltd.GotembaJapan
  2. 2.Ciphergen Biosystems Ltd.Camberley, SuureyUK

Personalised recommendations